HC Wainwright Has Positive Estimate for POAI Q4 Earnings

Predictive Oncology Inc. (NASDAQ:POAI) – Stock analysts at HC Wainwright upped their Q4 2025 earnings per share estimates for Predictive Oncology in a research note issued to investors on Friday, November 15th. HC Wainwright analyst S. Ramakanth now forecasts that the medical instruments supplier will post earnings of $0.06 per share for the quarter, up from their previous forecast of $0.05. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Predictive Oncology’s current full-year earnings is ($2.03) per share. HC Wainwright also issued estimates for Predictive Oncology’s FY2026 earnings at $0.08 EPS, FY2027 earnings at $0.27 EPS and FY2028 earnings at $0.46 EPS.

Predictive Oncology Stock Down 5.5 %

NASDAQ POAI opened at $0.64 on Monday. Predictive Oncology has a twelve month low of $0.55 and a twelve month high of $3.76. The firm has a market capitalization of $4.30 million, a PE ratio of -0.21 and a beta of 1.14. The stock’s 50 day moving average is $0.74 and its 200 day moving average is $1.05.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.